BRINGING UNTAPPED MEDTECH DISCOVERIES TO MARKET. Executive summary June 2013. QUATTROCENTO'S CAPITAL RAISING OF 15 M €.
Quattrocento is looking to develop its capacity to build and create innovative medtech companies with new shareholders who wish to bring their know-how and networks of relationships to the process.
Created in 2010 by experienced entrepreneurs in the medtech sector, Quattrocento transforms untapped discoveries of the leading public research labs in Paris into innovative medical technology products with strong commercial value, with a particular focus on measurement instruments for biotech research and diagnostic devices.
Create and build around ten subsidiaries in the next 5 years, of which at least 1 or 2 will achieve a substantial market presence and achieve a stock exchange listing
USE OF FUNDS
Create and launch new subsidiaries: 4 over the next 24 months
Finance the development of the 4 existing subsidiaries alongside new investors (external investors)
Reinforce the operational team with a technology/market analyst and a financial controller
Paris-based Quattrocento’s founders have assembled the resources and expertise to “industrialise” the seed stage of start-ups such that overcomes the obstacles to getting innovative products to market, more quickly and more cheaply:
Creation and development of businesses in close collaboration with researchers wishing to remain in their research labs
End-to-end process of execution and financing – Early evaluation of commercial potential; protection of intellectual property, development of an economic demonstrator, creation, as a subsidiary of Quattrocentro, of the company which will commercialise the product
Highly experienced team with all the skills and experience necessary to bring each project to fruition : science, marketing, development, strategy, intellectual property
Excellent sourcing giving early access to research projects
Based in the Latin Quarter of Paris, in close proximity to the leading research establishments, the Quattrocento team has close links with researchers, built over 15 years of collaboration
Good relationships with the technology transfer offices, which facilitates the development of the intellectual property of Quattrocento companies
Experienced entrepreneurial team
Highly complementary founding team members, with a blend of scientific, industrial and entrepreneurial expertise, having already collaborated on a medtechstartup, sold in 2011 at an attractive price
A committee of shareholder-experts, which advises on projects, and to whose members Quattrocento can outsource project requirements
Efficient use of resources
Pooling of expertise across Quattrocento’s subsidiaries
Financing of subsidiaries that closely follows the intensity of each phase of development
Active management of the portfolio of subsidiaries, with the flexibility to arbitrate between the continued development or sale of subsidiaries at every stage of the process
Quattrocento is structured as an industrial holding company with equity of 1.3M€
It derives its revenues from
Management fees from subsidiaries in the early stages of development
Dividends from profitable subsidiaries
…and its return on investment from the sale of portfolio companies
Quattrocento will propose, on the occasion of each exit, to distribute a part of the resulting capital gain to it shareholders
Investment in the subsidiaries will be made only via the holding company.
An innovative electrochemical system for detecting biological molecules (DNA, RNA, proteins), in advanced discussions with a major international distributor
Microfluidic systems for cell tests (pharma screening, toxicology), prototyped and ready for industrialisation
of which one is already profitable in 2 years
France has world class research but too few results of this research are transformed into innovative products due to two major obstacles specific to the country:
Complexity of the process of technology transfer (patent filing and negotiation of patent licenses) in the multi-layered system of French research and innovation
Lack of entrepreneurs with combined competencies in science, industry and business
A particularly acute problem in the medical technology sector (“medtech”), despite the opportunities that a global market of US$200 billion with sustained growth present.
BERTRAND FOURQUET - President
Prior to founding Quattrocento, he founded and managed Echosens, which develops innovative cirrhosis diagnostic equipment. Created in 2001, Echosens was sold 10 years later at an attractive price. Bertrand had previously gained business development experience creating and developing the Spanish subsidiaries of well known consumer brands. He began his career in mergers and acquisitions at Lazard Brothers and JP Morgan after graduating from ESSEC, one of France’s leading business schools
LUC TALINI - Chief Executive Officer
A founder of Quattrocento, Luc was previously CTO of Echosens. He has held a number of senior positions in leading research institutions. He worked for the technology transfer office of Paris Diderot university after leading the CEDIB project (creation of a centre for innovation in bioengineering). He had his first entrepreneurial experience with Genescore, which he created following his post at ESPCI in the neurobiology laboratory. Luc is an engineer and holds a doctorate in physics.
DAVID POIZAT - Technology And Quality Director
He joined Echosens in 2003 as head of industrialisation and production of the Fibroscanmedical system and quickly took over management of the company’s CE marking and Quality systems (obtaining ISO 13485 in 2005), finally directing the after-sales department. David is an Engineer in physics.
experts, all shareholders, advise on the projects as a committee and can also individually provide professional services to portfolio companies.
Theseexperts have over 220 years of combinedexperience:
Technical consulting; 3 PhDs: in Chemistry, Physics and Biomedicine; an expert in industrialcomputing; an expert in industrialisation and quality in the biomedicalsector; a specialist in communication and design, a humanresources expert, specialists in finance and marketing in the innovation/start-up sector, specialistsfrom non-medicalsectors able to bring cross-sectorknowledge and contacts, a specialist in fundraising and a marketresearcher in the medicalsector.
Elicel Alvéole lThamisl Azalée
ESTABLISHED: October 2009
ORIGINATING LABORATORY: Laboratory of MolecularElectrochemistry, Université Paris-Diderot
RESEARCH TEAM: Damien Marchal (Lecturer), Benoît Limoges (Head of Laboratory)
INTELLECTUAL PROPERTY: 3 patents
ESTABLISHED: December 2010
ORIGINATING LABORATORIES: Department of Physics and Biologyat the École Normale Supérieure (CNRS, ENS), Institut des Neurosciences de Bordeaux (CNRS UMR5297)
RESEARCH TEAM: Maxime Dahan (Head of Researchat CNRS), Vincent Studer (CNRS Researcher), Jean-Christophe Galas (CNRS Researcher)
INTELLECTUAL PROPERTY: 4 patents
Thamis’ technology is a patented method for measuring particle flow, based on the use of a matrix of scintillating plastic fibres connected to a digital camera. Thamis’ hodoscopes make it possible to measure beam profile and intensity. They have a very good dynamic range, are easy to use and require very little maintenance.
Field of application/market
Quality control of the particle beams used in hadrontherapy.
Hadrontherapy is a cancer treatment using a beam of particles (protons, carbon ions) to destroy X-ray-resistant and inoperable cancer cells. This highly effective method will have taken nearly 50 years to get off the ground on account of its infrastructure requirements which are both large (particle accelerator) and expensive (€100-150M). Since 2000, centres have been developing regularly across the globe. It is deemed that one centre can serve 10 million habitants; currently, in France, there are 2 centres (Orsay, Nice) in operation and 3 projects (Lyon, Caen and Toulouse).
State of progress
At an advanced stage of the launch phase, Thamis is in the process of producing a series of hodoscopes for MedAustron, an Austrian centre which is under construction.
Thamisaims to secure 1 order per year over the next 5 years.
ESTABLISHED: September 2011
ORIGINATING LABORATORIES: Prince-Ringuet Laboratory, Polytechnique/IN2P3/CNRS
Maurice Haguenauer (Head of Researchat CNRS/CERN),
Patrick Poilleux (CNRS Technician)
INTELLECTUAL PROPERTY: 1 patent
Azalée’s patented technology is based on the use of ultrasound to probe cortical bone and obtain structural and mechanical parameters.
Field of application/market
Medical devices to monitor the quality of cortical bone. A first application is currently under development to assess the fragility of the cortical bone in the context of osteoporosis, which affects approximately 200 million people across the globe, 40 % of whom are women over 50 years of age (and 20 % men). The fight against osteoporosis, on a constant rise due to the ageing of the population, is deemed in developed countries to be a major public health issue.
State of progress
Nearing completion of the assessment phase, a first demonstrator is being used in the laboratory to conduct ex-vivo tests on bones. The aim is to develop a demonstrator intended for a clinical pilot trial scheduled to start at the Cochin Department of Rheumatology in 2013, with a view to being brought to market in 2015.
ESTABLISHED: Summer 2012
ORIGINATING LABORATORY: Parametric Imaging Laboratory, Université Pierre-et-Marie-Curie, CNRS (UMR 7623)
RESEARCH TEAM: Pascal Laugier (Head of Laboratory),
Jean-Gabriel Minonzio (CNRS Researcher),
Maryline Talmant (CNRS Researcher),
Emmanuel Bossy (Lecturerat ESPCI)
INTELLECTUAL PROPERTY: 2 patents
68, Bd de Port-Royal 75005 Paris
R.C.S. 522 012 939